Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab (APHARIPE)
Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis
Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.
Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.
The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Hemophilia is a rare constitutional bleeding disorder. Severe hemophilia A corresponds to a severe factor VIII (FVIII) deficiency (<1%), and moderate hemophilia A to an FVIII level between 1% and 5%. Both forms manifest as spontaneous or post-traumatic/surgical intra-articular bleeds (hemarthroses) or muscle hematomas, which can jeopardize functional prognosis if recurrent.
Until April 2018, the treatment of severe and moderate hemophilia A was exclusively substitutive, relying on intravenous (IV) injections of clotting factor concentrates (FVIII, or bypassing agents such as rFVIIa or aPCC for patients with anti-FVIII inhibitors). Used both prophylactically (2 to 3 IV infusions per week) and on-demand for acute bleeds, this regimen enabled most patients-or family caregivers for younger children-to acquire and maintain autonomy in performing IV injections through frequent practice.
Since April 2018 for patients with inhibitors, March 2020 for severe hemophilia A without inhibitors, and January 2023 for moderate hemophilia A, subcutaneous prophylaxis with the monoclonal antibody emicizumab (Hemlibra®) has been available. While emicizumab converts the bleeding phenotype to that of mild hemophilia, it is strictly prophylactic; IV clotting factor infusions remain required in the event of breakthrough bleeding. Because bleeding events become very rare under emicizumab, the frequency of IV injections drops sharply.
The investigators hypothesize that patients (or family caregivers) who were previously autonomous in performing IV clotting factor infusions progressively lose technical competence and/or self-efficacy during emicizumab prophylaxis. APHARIPE is a multicenter, exploratory, non-interventional questionnaire-based study designed to evaluate patients' and caregivers' perceived loss of autonomy. Healthcare providers caring for this population will also be surveyed to assess potential perception gaps regarding the impact of this loss of autonomy on overall patient management.
The study aims to include 450 patients (or family caregivers) with severe or moderate hemophilia A treated with emicizumab who were previously autonomous for IV injections, over an 18-month recruitment period. Findings will help identify specific difficulties, question the relevance of ongoing IV injection training, assess the impact on acute bleed management and the need to keep emergency treatments at home, and ultimately optimize patient care pathways and therapeutic education practices
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nicolas GUERIN, Registered Nurse
- Phone Number: + 33 2 31 06 52 10
- Email: guerin-n@chu-caen.fr
Study Locations
-
-
-
Angers, France, 49933
- Centre Hospitalier Universitaire d'Angers
-
Contact:
- Julien DENIS LE SEVE, Medical Doctor
- Phone Number: +33 2 41 35 54 53
- Email: julien.denisleseve@chu-angers.fr
-
Bordeaux, France, 33076
- Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin
-
Contact:
- Sabine CASTET, Medical Doctor
- Phone Number: + 33 5 56 79 48 79
- Email: sabine-marie.castet@chu-bordeaux.fr
-
Bron, France, 69677
- Hospices Civiles de Lyon - Hôpital Louis Pradel
-
Contact:
- Séverine SEMLALI, Registered Nurse
- Phone Number: +33 4 72 11 88 10
- Email: severine.semlali@chu-lyon.fr
-
Caen, France, 14000
- Centre Hospitalier Universitaire de Caen
-
Contact:
- Nicolas GUERIN, Registered Nurse
- Phone Number: + 33 2 31 06 52 10
- Email: guerin-n@chu-caen.fr
-
Chambéry, France, 73011
- Centre Hospitalier Métropole Savoie
-
Contact:
- Valérie GAY, Medical Doctor
- Phone Number: + 33 4 79 96 61 83
- Email: Valerie.Gay@ch-metropole-savoie.fr
-
Clermont-Ferrand, France, 63000
- Centre Hospitalier Universitaire de Clermont Ferrand
-
Contact:
- Aurélien LEBRETON, Medical Doctor
- Phone Number: +33 4 73 75 00 65
- Email: alebreton@chu-clermontferrand.fr
-
Dijon, France, 21079
- Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand
-
Contact:
- Fabienne GENRE VOLOT, Medical Doctor
- Phone Number: +33 3 80 29 32 57
- Email: fabienne.volot@chu-dijon.fr
-
Grenoble, France
- Centre Hospitalier Universitaire de Grenoble
-
Contact:
- Raphaël MARLU, Medical Doctor
- Phone Number: +33 4 76 76 54 87
- Email: RMarlu@chu-grenoble.fr
-
Le Kremlin-Bicêtre, France, 94275
- AP-HP - Hôpital Bicêtre
-
Contact:
- Roseline D'OIRON, Medical Doctor
- Phone Number: +33 1 45 21 21 97
- Email: roseline.doiron@aphp.fr
-
Le Mans, France
- Centre Hospitalier du Mans
-
Contact:
- Johann ROSE, Medical Doctor
- Phone Number: +33 2 44 71 07 50
- Email: jrose@ch-lemans.fr
-
Lille, France, 59037
- Centre Hospitalier Régional Universitaire principal de la métropole lilloise
-
Contact:
- Antoine RAUCH, Medical Doctor
- Phone Number: +33 20 44 48 45
- Email: Antoine.RAUCH@chu-lille.fr
-
Marseille, France, 13385
- AP-HM - Hôpitaux Universitaires de Marseille Timone
-
Contact:
- Enora DIDIER, Registered Nurse
- Phone Number: +33 4 91 38 67 76
- Email: Enora.DIDIER@ap-hm.fr
-
Montpellier, France, 34295
- Centre Hospitalier Universitaire de Montpellier
-
Contact:
- Christine BIRON ANDREANI, Medical Doctor
- Phone Number: +33 4 67 33 77 71
- Email: c-biron@chu-montpellier.fr
-
Nantes, France, 44093
- Centre Hospitalier Universitaire Hôtel-Dieu
-
Contact:
- Marc TROSSAERT, Medical Doctor
- Phone Number: +33 2 40 08 74 68
- Email: marc.trossaert@chu-nantes.fr
-
Paris, France, 75679
- AP-HP - Hôpital Cochin
-
Contact:
- Stéphanie AGBOLO, Registered Nurse
- Phone Number: +33 1 58 41 20 13
- Email: stephanie.agbolo@aphp.fr
-
Poitiers, France, 86021
- Centre Hospitalier Universitaire de Poitiers - Hôpital Jean Bernard
-
Contact:
- Mathieu PUYADE, Medical Doctor
- Phone Number: +33 5 49 44 40 04
- Email: Mathieu.PUYADE@chu-poitiers.fr
-
Pringy, France, 74374
- Centre Hospitalier Annecy Gennevois
-
Contact:
- Claire REYNES, Medical Doctor
- Phone Number: +33 4 50 63 66 08
- Email: creynes@ch-annecygenevois.fr
-
Rennes, France
- Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
-
Contact:
- Odile ROUAULT, Registered Nurse
- Phone Number: +33 2 99 28 24 10
- Email: Odile.ROUAULT@chu-rennes.fr
-
Saint-Denis, France, 97400
- Centre Hospitalier Universitaire de la Réunion
-
Contact:
- Stéphane VANDERBECKEN, Medical Doctor
- Phone Number: +33 2 62 90 62 46
- Email: stephane.vanderbecken@chu-reunion.fr
-
Saint-Etienne, France, 45055
- Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord
-
Contact:
- Géraldine POUENOU, Medical Doctor
- Phone Number: +33 4 77 12 78 63
- Email: Geraldine.Poenou@chu-st-etienne.fr
-
Strasbourg, France, 67200
- Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
-
Contact:
- Agnès STROH LICHTENTHALER, Registered Nurse
- Phone Number: +33 3 88 12 80 97
- Email: Agnes.LICHTENTHALER@chru-strasbourg.fr
-
Toulouse, France, 31059
- Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
-
Contact:
- Caroline OUDOT CHALLARD, Medical Doctor
- Email: oudotchallard.c@chu-toulouse.fr
-
Tours, France, 37044
- Centre Hospitalier Régional Universitaire de Tours - Hôpital Trousseau
-
Contact:
- Laurent ARDILLON, Medical Doctor
- Phone Number: 033 2 47 47 46 15
- Email: L.ARDILLON@chu-tours.fr
-
Vandœuvre-lès-Nancy, France, 54500
- Centre Hospitalier Régional Universitaire de Nancy - Hôpital Brabois
-
Contact:
- Céline CHENUEL, Registered Nurse
- Phone Number: +33 3 83 15 37 84
- Email: C.CHENUEL@chru-nancy.fr
-
-
-
-
-
Pointe-à-Pitre, Guadeloupe, 97110
- Centre Hospitalier Universitaire de Pointe à Pitre - Hôpital Ricou
-
Contact:
- Scylia ALEXIS, Medical Doctor
- Phone Number: +33 5 90 89 16 72
- Email: scylia.alexis@chu-guadeloupe.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population consists of adult and minor patients with severe (FVIII <1%) or moderate (FVIII 1%-5%) hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year-or parent caregivers (excluding healthcare professionals) for non-autonomous minor patients-who were previously autonomous in performing intravenous clotting factor injections prior to emicizumab initiation. Healthcare professionals (physicians and nurses) involved in the care of these patients will also be enrolled. Participants will be recruited during routine clinical follow-up visits across participating French hemophilia treatment centers
Description
Inclusion Criteria:
For autonomous adult patients (patient enrolled in the study):
- Adult patient (>= 18 years old) with severe or moderate hemophilia A
- Receiving prophylactic treatment with emicizumab for more than 1 year
- Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
- Patient non-opposition obtained
For autonomous pediatric/minor patients (patient enrolled in the study):
- Minor patient (< 18 years old) with severe or moderate hemophilia A
- Receiving prophylactic treatment with emicizumab for more than 1 year
- Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
- Patient non-opposition obtained
- Non-opposition obtained from parents or legal guardians
For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):
- Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
- Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
- Parent caregiver non-opposition obtained
For healthcare providers:
- Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
- Healthcare provider non-opposition obtained
Exclusion Criteria:
For autonomous adult patients:
- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
For autonomous pediatric/minor patients:
- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
For non-autonomous pediatric/minor patients:
- Parent caregiver who is a healthcare professional
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients or Family Caregivers
Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy |
|
Healthcare Providers
Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Patients or Family Caregivers Reporting a Perceived Loss of Autonomy for Performing Intravenous Clotting Factor Injections
Time Frame: At baseline (single questionnaire completion)
|
Assessed using Question 9 of the study-specific patient/caregiver questionnaire (4-point Likert scale: "not at all autonomous", "slightly autonomous", "moderately autonomous", "completely autonomous"). Responses of "not at all autonomous", "slightly autonomous", or "moderately autonomous" will be classified as a perceived loss of autonomy. Expressed as absolute frequency and percentage of respondents |
At baseline (single questionnaire completion)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of Clotting Factor Concentrate Use Under Emicizumab Prophylaxis
Time Frame: At baseline (single questionnaire completion)
|
Absolute and relative frequency (percentage) of patients requiring intravenous clotting factor concentrates (FVIII or bypassing agents) while receiving emicizumab prophylaxis, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Patients Keeping Clotting Factor Concentrates at Home
Time Frame: At baseline (single questionnaire completion)
|
Percentage of patients who report having clotting factor concentrates (FVIII or bypassing agents) stored at home, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Patients or Caregivers Reporting Anticipated Difficulties With Performing a Future Intravenous Injection
Time Frame: At baseline (single questionnaire completion)
|
Percentage of patients or family caregivers who report experiencing or anticipating difficulties in performing a subsequent intravenous clotting factor injection, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Types of Difficulties Encountered During Intravenous Clotting Factor Injections
Time Frame: At baseline (single questionnaire completion)
|
Categorization and percentage distribution of specific technical or psychological difficulties reported by patients or family caregivers when performing intravenous injections, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Patients or Caregivers Expressing a Need for Home Nursing Assistance
Time Frame: At baseline (single questionnaire completion)
|
Percentage of patients or family caregivers reporting the need for a community nurse (IDE) to perform repeated intravenous clotting factor injections, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Patients Expressing a Need for a Therapeutic Patient Education Program
Time Frame: At baseline (single questionnaire completion)
|
Percentage of patients reporting the need for therapeutic education sessions to maintain their autonomy in performing intravenous clotting factor injections, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Patients or Caregivers Expressing a Need for Initial Intravenous Injection Training
Time Frame: At baseline (single questionnaire completion)
|
Percentage of patients or family caregivers reporting the need for initial training to learn how to perform intravenous clotting factor injections, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Frequency and Quantity of Unused Expired Clotting Factor Concentrates at Home
Time Frame: At baseline (single questionnaire completion)
|
Absolute and relative frequency (percentage) of patients having unused expired FVIII concentrates or bypassing agents at home, along with the total number of expired doses reported via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Patients or Caregivers Reporting an Impact of Perceived Loss of Autonomy on Bleeding Event Management
Time Frame: At baseline (single questionnaire completion)
|
Absolute and relative frequency (percentage) of patients or family caregivers reporting that their perceived loss of autonomy negatively affected the management of an acute bleeding episode, assessed via the patient/caregiver questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Healthcare Providers Supporting the Maintenance of Patient or Caregiver Autonomy for Intravenous Injections
Time Frame: At baseline (single questionnaire completion)
|
Percentage of healthcare professionals who consider it necessary to maintain patients' or family caregivers' autonomy for intravenous administration of clotting factor concentrates, assessed via the healthcare provider questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Healthcare Providers Supporting the Maintenance of Clotting Factor Concentrates at Home
Time Frame: At baseline (single questionnaire completion)
|
Percentage of healthcare professionals who consider it necessary to keep emergency clotting factor concentrates at patients' homes, assessed via the healthcare provider questionnaire |
At baseline (single questionnaire completion)
|
|
Proportion of Healthcare Providers Perceiving a Delay in Bleeding Management Due to Reduced Patient Autonomy
Time Frame: At baseline (single questionnaire completion)
|
Percentage of healthcare professionals who consider that a decreased sense of autonomy for performing intravenous injections delays the management of acute bleeding episodes, assessed via the healthcare provider questionnaire |
At baseline (single questionnaire completion)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nicolas GUERIN, Registered Nurse, Centre Hospitalier Universitaire de Caen - Centre de Ressources et de Compétences Maladies Hémorragiques Rares
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 26-0006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.